-
-
-
-
-
-
-
Exelixis (EXEL) Reports Prelim FY23 Results, Issues 2024 Guidance
-
-
-
-
-
-
-
Exelixis to Release Second Quarter 2023 Financial Results on Tuesday, August 1, 2023
-
-
-
-
-
-
-
Exelixis Reiterates Commitment to Shareholder Value Creation
-
-
-
-
-
-
-
Exelixis to Release Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 7, 2023
-
-
-
-
-
-
-
Exelixis to Release Second Quarter 2022 Financial Results on Tuesday, August 9, 2022
-
-
-
-
-
-
-
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Continued Survival Benefits with Over Two Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal C
-
-
-
-
-
-
-
Exelixis Statement on the Passing of Two Senior Executives
-
973,681 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All